Mount Sinai spin-off that aims to predict autism and ALS from a strand of hair wins $16 million

A subsidiary of New York-based Mount Sinai Health System, which aims to predict autism in babies with a single strand of hair, has raised $16 million in Series A funding.

LinusBio is developing a platform to identify accurate exposure biomarkers for conditions such as childhood cancer, inflammatory bowel disease, psychosis, schizophrenia and amyotrophic lateral sclerosis or ALS.

“Our mission is simple: to provide better outcomes for people and families suffering from complex diseases,” said Manish Arora, MD, co-founder and CEO of LinusBio and professor at the Icahn School of Medicine at Mount Sinai. January 12th. news release. “We decided to focus on autism first for many reasons, an important one being a completely different trajectory in cases of early detection and effective intervention.”

LinusBio, developed with Mount Sinai Innovation Partners, said one of its first technologies could predict the likelihood of autism at birth with 80 to 90 percent accuracy.

The funding round was led by GreatPoint Ventures and Bow Capital.

Content Source

California Press News – Latest News:
Los Angeles Local News || Bay Area Local News || California News || Lifestyle News || National news || Travel News || Health News

Related Articles

Back to top button